Orexo AB (Sweden) Insiders
ORX Stock | SEK 12.88 0.58 4.72% |
Orexo AB employs about 126 people. The company is managed by 9 executives with a total tenure of roughly 52 years, averaging almost 5.0 years of service per executive, having 14.0 employees per reported executive. Breaking down Orexo AB's management performance can provide insight into the firm performance.
Nikolaj Sorensen CEO Pres CEO |
Cecilia Coupland President Vice President and Head of Operations |
Orexo |
Orexo AB Management Team Effectiveness
The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.Orexo AB Workforce Comparison
Orexo AB is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 457. Orexo AB totals roughly 126 in number of employees claiming about 28% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.29) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.29. Orexo AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Orexo AB Price Series Summation is a cross summation of Orexo AB price series and its benchmark/peer.
Orexo AB Notable Stakeholders
An Orexo AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Orexo AB often face trade-offs trying to please all of them. Orexo AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Orexo AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nikolaj Sorensen | Pres CEO | Profile | |
Cecilia Coupland | Vice President and Head of Operations | Profile | |
Robert DeLuca | President of Orexo US Inc. | Profile | |
Robert Ronn | Vice President and Head of Research & Development | Profile | |
Fredrik Jarrsten | Ex CFO | Profile | |
MD MBA | Chief Officer | Profile | |
Lena Wange | Investor Relations & Communications Manager | Profile | |
Jesper Lind | Advisor | Profile | |
Dennis Urbaniak | Ex Therapeutics | Profile |
About Orexo AB Management Performance
The success or failure of an entity such as Orexo AB often depends on how effective the management is. Orexo AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Orexo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Orexo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Orexo AB , a specialty pharmaceutical company, develops products based on proprietary drug delivery technology. Orexo AB was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 130 people.
Please note, the imprecision that can be found in Orexo AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Orexo AB. Check Orexo AB's Beneish M Score to see the likelihood of Orexo AB's management manipulating its earnings.
Orexo AB Workforce Analysis
Traditionally, organizations such as Orexo AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Orexo AB within its industry.Orexo AB Manpower Efficiency
Return on Orexo AB Manpower
Revenue Per Employee | 5M | |
Revenue Per Executive | 69.4M | |
Net Loss Per Employee | 1.5M | |
Net Loss Per Executive | 20.4M | |
Working Capital Per Employee | 4.4M | |
Working Capital Per Executive | 61.4M |
Additional Tools for Orexo Stock Analysis
When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.